Aclaris Therapeutics Earns 'Moderate Buy' Rating from Analysts

Shares of the biotech company have received consensus recommendation from analysts covering the stock.

Mar. 14, 2026 at 8:43am

Got story updates? Submit your updates here. ›

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has earned a 'Moderate Buy' consensus rating from the seven analysts currently covering the stock, according to Marketbeat.com. One analyst has rated the stock as a 'sell', five have assigned a 'buy' recommendation, and one has given a 'strong buy' rating. The average 12-month price target among the analysts is $9.80.

Why it matters

Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel treatments for dermatological conditions. The 'Moderate Buy' rating from analysts suggests they see potential in the company's pipeline and believe the stock is undervalued at current levels.

The details

Several research analysts have recently weighed in on Aclaris Therapeutics. Weiss Ratings reissued a 'sell (d-)' rating on the stock, while HC Wainwright reaffirmed a 'buy' rating and $16.00 price target. Craig Hallum initiated coverage on the stock with a 'buy' rating and $10.00 price target, and Wall Street Zen downgraded the stock from 'hold' to 'sell'.

  • Aclaris Therapeutics shares opened at $3.54 on Friday, March 14, 2026.
  • The stock has a 52-week low of $1.05 and a 52-week high of $4.89.

The players

Aclaris Therapeutics, Inc.

A clinical-stage biopharmaceutical company focused on developing novel treatments for dermatological conditions.

Weiss Ratings

An investment research firm that provides ratings and analysis on stocks.

HC Wainwright

An investment banking firm that provides research coverage on Aclaris Therapeutics.

Craig Hallum

An investment research firm that initiated coverage on Aclaris Therapeutics.

Wall Street Zen

An investment research firm that downgraded Aclaris Therapeutics from 'hold' to 'sell'.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.